Objective: The objective of conducting this study was to evaluate the expression of iNOS in mouse experimental model of PD.

Background: Parkinson’s Disease (PD) is one of the most common neurodegenerative diseases. Several molecular mechanisms are involved.

Method: PD was induced through injecting mice with 10 doses of MPTP (25 mg/kg) and probenecid (250 mg/kg). Mice in control group were injected by saline (25 mg/kg). Immunohistochemical stains for iNOS in brain sections were carried out using indirect immunoperoxidase techniques

Results: Study findings showed that there was a significant difference in the expression level iNOS in study groups (P<0.001) and experimental PD group had more expressed iNOS levels compared with control group. Taken together, the present study confirmed the impact of induction of iNOS in the etiology of PD

Conclusion: The present study confirmed the impact of induction of iNOS in the etiology of PD.

References: Al-Jarraha. M, Jamous. M, Al Zailaey. K, Bweird. S (2010). Endurance exercise training promotes angiogenesis in the brain of chronic/progressive mouse model of Parkinson’s disease, NeuroRehabilitation, 26: 369–373. Ara. J, Przedborski. S, Naini. A, Jackson-Lewis. V, Trifiletti.R, Horwitz.J, and et al (1998). Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), Proc. Natl. Acad. Sci. USA, 95:7659–7663. Dishman .R, Berthoud. H-R, Booth. F, Cotman . C, Edgerton. V. R, Fleshner .M. R, et al, Neurobiology of Exercise, OBESITY , 2006;14 (3 ) : 345- 356. Hancock .D, Martin. E, Vance. J, Scotts. W (2008). Nitric oxide synthase genes and their interactions with environmental factors in Parkinson’s disease. Neurogenetics, 9 (4):249–262. Jankovic J (2008). Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry, 79(4):368-76. Juurlink. B, Management of Oxidative Stress in the CNS: The Many Roles of Glutathione, Nettrotoxicity Research, 1999; 1: 119-140. Kazim Husain, Stephen R. Hazelrigg (2002). Oxidative injury due to chronic nitric oxide synthase inhibition in rat: effect of regular exercise on the heart. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 1587 (1): 75-82. Kroncke. K, Fehsel. K, Kolb- Bachofen. V (1998). Inducible NOS in human disease. Clin Exp Immunol, 113: 147-156. Larsen JP, Dupont E, Tandberg E (1994). Clinical diagnosis of Parkinson’s disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand, 89(4):242-51. Moncada. S, Higgs. A, Furchgott. R. XIV (1997). International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacological Reviews 49:137-142. Przedborski. S, Jackson-Lewis. V, Yokoyama .R, Shibata. T, Dawson. V, Dawson .T (1996). Role of neuronal nitric oxide in 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Neurobiology, 93:4565-4571. Rao G, Fisch L, Srinivasan S, D’Amico F, Okada T, Eaton C, et al (2003). Does this patient have Parkinson disease? JAMA, 289(3):347-53. Seet. R.C.S, Lee. J, Lim. E, Tan. J, Quek. A, Chong. W-L, et al (2010). Oxidative damage in Parkinson disease: Measurement using accurate biomarkers, Free Radical Biology & Medicine, 48: 560–566. Tolosa E, Wenning G, Poewe W (2006). The diagnosis of Parkinson’s disease. Lancet Neurol, 5(1):75-86. Tuncel. D, Tolun. F, Toru. I (2009). Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson’s disease. Mediators of Inflammation, 2009:1- 4.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-expression-of-inos-in-mouse-experimental-model-points-to-inflammatory-conditions-associated-with-parkinsons-disease/